COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00006383
Recruitment Status : Completed
First Posted : May 30, 2003
Last Update Posted : November 6, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of liposomal vincristine in treating patients who have refractory or relapsed non-Hodgkin's lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Drug: liposomal vincristine sulfate Phase 2

Detailed Description:


  • Determine the complete and partial tumor responses in patients with aggressive non-Hodgkin's lymphoma that is refractory to or relapsed after second-line combination chemotherapy treated with vincristine sulfate liposomes injection.
  • Determine the toxicity of this treatment regimen in these patients.
  • Determine the duration of response, time to progression, and survival in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive vincristine sulfate liposomes IV over 1 hour. Treatment repeats every 2 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 8 weeks until disease progression.

PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B-Cell Non-Hodgkin's Lymphoma That is Refractory or Relapsed After Second-Line Combination Chemotherapy Revised Title Per 03/01 SR Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Aggressive Non-Hodgkin's Lymphoma That is Refractory to or Relapsed After Second-Line Combination Chemotherapy
Study Start Date : June 2000
Actual Study Completion Date : August 2009

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed aggressive non-Hodgkin's lymphoma including:

    • Peripheral T-cell lymphoma not otherwise specified
    • Anaplastic large null-/T-cell lymphoma
    • Diffuse large B-cell lymphoma including:

      • Primary mediastinal large B-cell lymphoma with sclerosis
      • Intravascular large B-cell lymphoma
      • Immunoblastic B-cell lymphoma
      • T-cell-rich B-cell lymphoma
      • Anaplastic large B-cell lymphoma
  • At least one bidimensionally measurable lesion with clearly defined margins at least 2 cm in the largest dimension by physical examination or CT scan
  • No prior or active CNS lymphoma or AIDS-related lymphoma
  • Must have received 2 or more prior chemotherapy courses from time of diagnosis of aggressive lymphoma or from time of biopsy-proven transformation from indolent to aggressive

    • Prior first and second-line therapy must have been combination chemotherapy
    • Prior first-line chemotherapy regimen must have contained anthracycline
    • Must have had at least a minor response to first-line therapy



  • 18 and over

Performance status:

  • ECOG 0-3

Life expectancy:

  • Not specified


  • Granulocyte count at least 500/mm^3 (unless due to lymphoma bone marrow involvement)
  • Platelet count at least 50,000/mm^3 (unless due to lymphoma bone marrow involvement)


  • Bilirubin no greater than 2 times upper limit of normal (ULN)
  • ALT no greater than 4 times ULN
  • Alkaline phosphatase no greater than 4 times ULN


  • Not specified


  • No prior neurological disorders unrelated to chemotherapy (including familial neurological diseases or acquired demyelinating disorders)
  • No neuromuscular impairment (neuromotor, neurosensory, or neurocerebellar)
  • No prior grade 3 or 4 sensory or motor neuropathy related to chemotherapy


  • No uncontrolled severe medical illness or infection
  • HIV negative
  • No other malignancies within the past 5 years except curatively resected basal cell skin cancer or carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • See Radiotherapy
  • No prior allogeneic bone marrow or peripheral blood stem cell transplantation
  • At least 4 weeks since prior immunotherapy
  • No concurrent biological agents


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy

Endocrine therapy:

  • At least 4 weeks since prior corticosteroids at a dose greater than 10 mg/day of prednisone or equivalent


  • Prior involved-field radiotherapy allowed if irradiated area is not the only source of measurable disease
  • Prior total body radiotherapy with high-dose therapy and autologous stem cell transplantation allowed
  • At least 4 weeks since prior radiotherapy
  • No concurrent radiotherapy to any disease site


  • At least 4 weeks since prior major surgery except for diagnosis of lymphoma
  • No concurrent surgical removal of any indicator lesion


  • At least 4 weeks since prior alternative or investigational anticancer treatment
  • No other concurrent systemic anticancer therapy
  • No other concurrent investigational drug
  • No concurrent phenytoin
  • No concurrent hepatic drug metabolism inhibitors or inducers (cytochrome P450 isoenzymes in the CYP 3A subfamily)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00006383

Layout table for location information
United States, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States, 90033-0804
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
United States, Illinois
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611-3013
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, United States, 62526
United States, Ohio
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States, 44195
United States, Texas
University of Texas Health Center at Tyler
Tyler, Texas, United States, 75708
United States, Vermont
Vermont Cancer Center
Burlington, Vermont, United States, 05401-3498
Canada, Alberta
Tom Baker Cancer Center - Calgary
Calgary, Alberta, Canada, T2N 4N2
Sponsors and Collaborators
Inex Pharmaceuticals
Layout table for investigator information
Study Chair: Barbara Gallimore, PhD Inex Pharmaceuticals
Publications of Results:
Layout table for additonal information Identifier: NCT00006383    
Other Study ID Numbers: CDR0000068259
First Posted: May 30, 2003    Key Record Dates
Last Update Posted: November 6, 2013
Last Verified: December 2002
Keywords provided by National Cancer Institute (NCI):
recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult T-cell leukemia/lymphoma
anaplastic large cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action